Sign Up
OverviewAPI
Faron Pharmaceuticals is hosting a webcast to discuss new data from the Phase I/II BEXMAB study of bexmarilimab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), providing an update on the development outlook for the next 6-9 months. The company also held an extraordinary general meeting (EGM) in Turku, Finland, approving proposals of the Board of Directors and electing new members. Dr. Birge Berns has been appointed as the interim Chief Medical Officer, while Dr. Marie-Louise Fjällskog will step down and be nominated to the company's Board of Directors. Faron Pharmaceuticals is focused on developing novel immunotherapies for cancers, with strong objective responses in its clinical Phase I/II BEXMAB study of bexmarilimab.

Ask a question